| Drug Name: | Spironolactone (52-01-7) |
|---|---|
| PubChem ID: | 5833 |
| SMILES: | CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C |
| InchiKey: | LXMSZDCAJNLERA-ZHYRCANASA-N |
| Therapeutic Category: | Diuretics, Hormone Antagonists, Hormones, Mineralocorticoid Receptor Antagonists, Natriuretic Agents |
| Molecular Weight (dalton) | : | 416.583 |
| LogP | : | 4.8523 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 60.44 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Mitomycin (50-07-7) | Diarrhoea | Antagonistic | Not understood | Mitotane Spironolactone antagonism in Cushing's syndrome |
| Mitomycin (50-07-7) | Nausea | Antagonistic | Not understood | Mitotane Spironolactone antagonism in Cushing's syndrome |
| Candesartan (139481-59-7) | Hyperkalaemia | Antagonistic | Candesartan reduces the levels of aldosterone, which results in the retention of potassium | Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category